Furthermore, the combination of AT-II and AT-III with FDA-approved drugs enhanced sensitivity in XPC-KD-resistant renal cell carcinoma (RCC) cells, overcoming XPC deficiency-mediated resistance [74]. The gene discussed is SERPINC1; the disease is renal cell carcinoma.